¼¼°èÀÇ À§¾Ï Áø´Ü ÀýÂ÷ ½ÃÀå º¸°í¼­(2025³â)
Gastric Cancer Diagnostic Procedure Global Market Report 2025
»óǰÄÚµå : 1824380
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 250 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,457,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,334,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 12,211,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

À§¾Ï Áø´Ü ÀýÂ÷ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ °­·ÂÇÑ ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù. 2029³â¿¡´Â CAGR 7.5%¸¦ ³ªÅ¸³» 20¾ï 6,000¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ¼ºÀåÀº POC(Point-of-Care) °Ë»ç Áõ°¡, ½Å±Ô ¹ÙÀÌ¿À¸¶Ä¿ÀÇ µµÀÔ, ¸ÂÃãÇü ÀÇ·á·ÎÀÇ ½ÃÇÁÆ®, Â÷¼¼´ë ½ÃÄö½ÌÀÇ Ã¤¿ë, ³»½Ã°æ À̹Ì¡ ¸ð´Þ¸®Æ¼ÀÇ °­È­ µî¿¡ ±âÀÎÇÕ´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ³ª³ë±â¼úÀÇ ÅëÇÕ, ºòµ¥ÀÌÅÍ ºÐ¼®ÀÇ Ã¤¿ë, ¹Ì»ý¹°ÃÑ ºÐ¼®ÀÇ ÀÀ¿ë, ȯÀÚ Áß½ÉÀÇ Á¢±Ù Áõ°¡, Áø´Ü¿¡ À־ ¿ø°ÝÀÇ·áÀÇ ¿ªÇÒ µîÀÌ ÀÖ½À´Ï´Ù.

ÇâÈÄ 5³â°£ÀÇ ¼ºÀå·ü 7.5%¶ó°í ÇÏ´Â ¿¹ÃøÀº ÀüȸÀÇ ¿¹ÃøÀ¸·ÎºÎÅÍ 0.1%ÀÇ ¼ÒÆøÀÇ °¨¼Ò¸¦ ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. ÀÌ °¨¼Ò´Â ÁÖ·Î ¹Ì±¹°ú ´Ù¸¥ ±¹°¡ °£ÀÇ °ü¼¼ÀÇ ¿µÇâ ¶§¹®ÀÔ´Ï´Ù. °ü¼¼ÀÇ ºÎ°ú´Â ÀϺ»°ú ³×´ú¶õµå¿¡¼­ Á¶´ÞÇÏ´Â ÃÊÀ½ÆÄ ³»½Ã°æ(EUS) ¹üÀ§¿Í »ý°Ë Áý°ÔÀÇ ºñ¿ëÀ» »ó½Â½Ã۰í Á¶±â ¹ß°ßÀ» ÇØÄ¡Áö ¾Ê°í ¼ÒÈ­±â(GI) ³»½Ã°æ °Ë»ç ´Ü°¡¸¦ ÀλóÇÒ ¼ö Àֱ⠶§¹®¿¡ Å« °úÁ¦°¡ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ »óÈ£ °ü¼¼¿Í ¹«¿ª ±äÀå Áõ°¡¿Í Á¦ÇÑÀ¸·Î ÀÎÇÑ ¼¼°è °æÁ¦¿Í ¹«¿ª¿¡ ´ëÇÑ ¾Ç¿µÇâÀ¸·Î ÀÎÇØ ±× ¿µÇâÀÌ ´õ ±¤¹üÀ§ÇÏ°Ô ´Ã¾î³¯ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¼ÒÈ­±â ÁúȯÀÇ À¯º´·ü Áõ°¡´Â À§¾Ï Áø´Ü ÀýÂ÷ ½ÃÀå ¼ºÀå ±â´ëÀÇ ¿øµ¿·ÂÀÔ´Ï´Ù. ¼ÒÈ­±â ÁúȯÀº °£°ú ÃéÀåÀ» Æ÷ÇÔÇÑ ¼ÒÈ­±â°è ¹× À̸¦ Áö¿øÇÏ´Â Àå±âÀÇ ´Ù¾çÇÑ ºÎºÐ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ´Ù¾çÇÑ Áúº´À» Æ÷°ýÇÕ´Ï´Ù. À§¾Ï Áø´Ü ÀýÂ÷´Â ³»½Ã°æ °Ë»ç³ª »ý°Ë µîÀÇ ¹æ¹ýÀ¸·Î À§¾Ï¿¡ ´ëóÇϱâ À§ÇØ ÇʼöÀûÀÔ´Ï´Ù. µû¶ó¼­ ¼ÒÈ­±â ÁúȯÀÇ ÀÌȯÀ² È®´ë´Â ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î ¹Ì±¹¿¡ º»»ç¸¦ µÐ ¼ÒÈ­±â³»°ú Àü¹® ÀÇ·á½Ã¼³ GI Associates & Endoscopy Center°¡ ½Ç½ÃÇÑ Á¶»ç¿¡¼­´Â 33°³±¹¿¡¼­ 7¸¸ 3,076¸íÀÌ Âü°¡ÇßÀ¸¸ç, 2022³â 8¿ù¿¡´Â ´ë»óÀÚÀÇ 40%°¡ ±â´É¼º ¼ÒÈ­±â ÁúȯÀ» ¾Î°í ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. µû¶ó¼­ ¼ÒÈ­±âÁúȯÀÇ À¯º´·ü Áõ°¡´Â À§¾Ï Áø´Ü ÀýÂ÷ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â Áß¿äÇÑ ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå : ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï°ú °ü¼¼, ±×¸®°í Äڷγª ¹× ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

KTH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The diagnostic procedure for gastric cancer involves the identification and treatment of cancerous cells in the stomach. This procedure is crucial for diagnosing stomach cancer.

Key procedures in the diagnostic process for gastric cancer include endoscopic procedures, biopsies, tissue tests, laboratory tests, in-vitro diagnostic tests, imaging tests, molecular diagnostics, multiplexing molecular diagnostics, immunoassays, and others. The endoscopic procedure involves the examination of internal organs, such as the gastrointestinal tract, by inserting a long, thin tube directly into the body. This endoscopy procedure is utilized in gastric cancer diagnosis, addressing both symptomatic and asymptomatic cases, and encompasses instruments, reagents and consumables, and services. Various body fluids, including blood, urine, saliva, stomach juice, and tissue, are required for the procedure. These fluids aid in the detection and treatment of both early and advanced gastric cancer.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The gastric cancer diagnostic procedure market research report is one of a series of new reports from The Business Research Company that provides gastric cancer diagnostic procedure market statistics, including the gastric cancer diagnostic procedure industry's global market size, regional shares, competitors with a gastric cancer diagnostic procedure market share, detailed gastric cancer diagnostic procedure market segments, market trends, and opportunities, and any further data you may need to thrive in the gastric cancer diagnostic procedure industry. This gastric cancer diagnostic procedure market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gastric cancer diagnostic procedure market size has grown strongly in recent years. It will grow from $1.44 billion in 2024 to $1.54 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to innovations in biopsy techniques, increased research funding, evolution of biomarker discovery, improved pathological analysis, shifts in screening guidelines.

The gastric cancer diagnostic procedure market size is expected to see strong growth in the next few years. It will grow to $2.06 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to rise in point-of-care testing, introduction of novel biomarkers, shift towards personalized medicine, adoption of next-generation sequencing, enhanced endoscopic imaging modalities. Major trends in the forecast period include integration of nanotechnology, adoption of big data analytics, application of microbiota analysis, increased patient-centric approaches, role of telehealth in diagnostics.

The forecast of 7.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge by increasing costs for endoscopic ultrasound (EUS) scopes and biopsy forceps sourced from Japan and the Netherlands, potentially compromising early detection and raising gastrointestinal(GI) endoscopy unit expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of gastrointestinal diseases is a driving force behind the anticipated growth in the gastric cancer diagnostic procedure market. Gastrointestinal disorders encompass a range of illnesses affecting various sections of the digestive system and supporting organs, including the liver and pancreas. The gastric cancer diagnostic procedure is essential for addressing stomach cancer through methods such as endoscopy and biopsy. Therefore, the expanding incidence of gastrointestinal diseases is contributing to the market's growth. For instance, a study conducted by GI Associates & Endoscopy Center, a US-based medical facility specializing in gastroenterology services, involved 73,076 people from 33 nations, revealing that 40% of the subjects suffered from a functional gastrointestinal illness in August 2022. Hence, the increasing prevalence of gastrointestinal diseases is a significant factor propelling the growth of the gastric cancer diagnostic procedure market.

The rising prevalence of smoking is expected to drive the growth of the gastric cancer diagnostic procedure market in the future. Smoking involves the inhalation and exhalation of smoke produced by burning tobacco or other substances. Gastric cancer diagnostic procedures play a crucial role for individuals with a history of smoking or those at risk of smoking-related cancers by enabling early detection, identifying precancerous lesions, developing personalized treatment plans, facilitating communication and coordination, and providing a comprehensive assessment of the gastric mucosa and surrounding tissues. According to a report by The World Health Organization, a Switzerland-based intergovernmental organization, in July 2023, more than 8 million people are killed by tobacco each year, including 1.3 million non-smokers who inhale second-hand smoke. Therefore, the rising prevalence of smoking is a key driver of the growth of the gastric cancer diagnostic procedure market.

Technological advancements represent a prominent trend gaining momentum in the gastric cancer diagnostic market. Leading companies in the gastric cancer diagnostic market are actively incorporating new technologies to maintain their competitive positions. For example, in June 2022, Ibex Medical Analytics, an Israel-based provider of AI-powered diagnostics for health organizations, introduced Galen Gastric, the world's first AI-powered solution designed for gastric cancer detection. Galen Gastric serves as an integrated diagnostic tool assisting pathologists in identifying stomach cancer, H. pylori, and other critical clinical findings, contributing to faster turnaround times and improved diagnostic workflows.

Prominent companies in the gastric cancer diagnostic procedure market are strategically focusing on innovative products such as tissue staining platforms to drive revenue growth. The tissue staining platform aims to deliver rapid and precise test results, enabling medical professionals to make timely decisions regarding patient care. In June 2022, F. Hoffmann-La Roche AG, a Switzerland-based healthcare company, introduced the benchmark ultra plus system. This system, building on the proven technology of the benchmark ultra system, provides a fully automated workflow for immunohistochemistry (IHC) and in-situ hybridization (ISH) slide staining. It enhances the laboratory experience with features such as a retractable work surface, improved sliding drawers, indicator lights, and remote monitoring via a connected device, addressing user feedback. The system emphasizes efficient workflow, testing efficiency, and eco-friendly attributes.

In March 2023, Pfizer, a pharmaceutical corporation based in the United States, acquired Seagen Inc. for $43 billion. This acquisition strengthens Pfizer's position as a leading player in the oncology market by incorporating Seagen's groundbreaking antibody-drug conjugate (ADC) technology and expanding its portfolio of innovative cancer therapies. Seagen Inc. is a US-based biotechnology company focused on the discovery, development, and commercialization of transformative cancer medicines.

Major companies operating in the gastric cancer diagnostic procedure market include Pfizer Inc., Johnson & Johnson Co, F. Hoffmann La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories Inc., Sanofi SA, Eli Lilly and Company, Otsuka Pharmaceutical Co Ltd., AdventHealth, Atrium Health, Astellas Pharma Inc, Bausch Health Companies Inc., Agilent Technologies Inc., Ipsen Pharma, Hartford HealthCare, Myriad Genetics Inc., NovoCure Limited, Foundation Medicine Inc., Biocept Inc.

North America was the largest region in the gastric cancer diagnostics procedure market in 2024. The regions covered in the gastric cancer diagnostic procedure market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the gastric cancer diagnostic procedure market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gastric cancer diagnostics procedure market includes revenues earned by entities that provide diagnostic procedures such as surgery, chemotherapy, and radiation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gastric Cancer Diagnostic Procedure Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gastric cancer diagnostic procedure market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for gastric cancer diagnostic procedure ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gastric cancer diagnostic procedure market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Gastric Cancer Diagnostic Procedure Market Characteristics

3. Gastric Cancer Diagnostic Procedure Market Trends And Strategies

4. Gastric Cancer Diagnostic Procedure Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Gastric Cancer Diagnostic Procedure Growth Analysis And Strategic Analysis Framework

6. Gastric Cancer Diagnostic Procedure Market Segmentation

7. Gastric Cancer Diagnostic Procedure Market Regional And Country Analysis

8. Asia-Pacific Gastric Cancer Diagnostic Procedure Market

9. China Gastric Cancer Diagnostic Procedure Market

10. India Gastric Cancer Diagnostic Procedure Market

11. Japan Gastric Cancer Diagnostic Procedure Market

12. Australia Gastric Cancer Diagnostic Procedure Market

13. Indonesia Gastric Cancer Diagnostic Procedure Market

14. South Korea Gastric Cancer Diagnostic Procedure Market

15. Western Europe Gastric Cancer Diagnostic Procedure Market

16. UK Gastric Cancer Diagnostic Procedure Market

17. Germany Gastric Cancer Diagnostic Procedure Market

18. France Gastric Cancer Diagnostic Procedure Market

19. Italy Gastric Cancer Diagnostic Procedure Market

20. Spain Gastric Cancer Diagnostic Procedure Market

21. Eastern Europe Gastric Cancer Diagnostic Procedure Market

22. Russia Gastric Cancer Diagnostic Procedure Market

23. North America Gastric Cancer Diagnostic Procedure Market

24. USA Gastric Cancer Diagnostic Procedure Market

25. Canada Gastric Cancer Diagnostic Procedure Market

26. South America Gastric Cancer Diagnostic Procedure Market

27. Brazil Gastric Cancer Diagnostic Procedure Market

28. Middle East Gastric Cancer Diagnostic Procedure Market

29. Africa Gastric Cancer Diagnostic Procedure Market

30. Gastric Cancer Diagnostic Procedure Market Competitive Landscape And Company Profiles

31. Gastric Cancer Diagnostic Procedure Market Other Major And Innovative Companies

32. Global Gastric Cancer Diagnostic Procedure Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gastric Cancer Diagnostic Procedure Market

34. Recent Developments In The Gastric Cancer Diagnostic Procedure Market

35. Gastric Cancer Diagnostic Procedure Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â